HKD 5.36
(-1.83%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 365.05 Million CNY | -4.61% |
2022 | 382.71 Million CNY | 73.63% |
2021 | 220.41 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 80.85 Million HKD | -60.19% |
2024 Q2 | 80.16 Million HKD | -0.15% |
2023 Q4 | 207.13 Million HKD | 74.77% |
2023 FY | 365.05 Million CNY | -4.61% |
2023 Q3 | 118.51 Million HKD | -33.7% |
2023 Q2 | 178.74 Million HKD | 78.14% |
2023 Q1 | 100.33 Million HKD | -54.86% |
2022 FY | 382.71 Million CNY | 73.63% |
2022 Q4 | 222.27 Million HKD | 99.8% |
2022 Q3 | 111.24 Million HKD | -40.34% |
2022 Q2 | 186.47 Million HKD | 0.0% |
2021 FY | 220.41 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | -12.309% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 50.618% |